The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults.

The development marks the fifth approved indication of the drug since October 2023. The US Food and Drug Administration has approved bimekizumab, a humanized interleukin -17A and IL-17F antagonist, ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

▎药明康德内容团队编辑优时比（UCB）今天宣布，美国FDA已批准Bimzelx（bimekizumab）用于治疗中度至重度化脓性汗腺炎（HS）成人患者。根据新闻稿，Bimzelx是可同时选择性抑制白介素17A（IL-17A）和白介素17F（IL-17 ...

For patients with axial spondyloarthritis (axSpA) who experience extra musculoskeletal symptoms such as acute anterior uveitis, bimekizumab (BKZ) may offer protective benefits, according to study ...

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.

Bimekizumab was statistically superior to Humira in achieving rapid response, defined as PASI 75 at week four. During a dose-blind maintenance period, high levels of skin clearance were maintained ...

Bimekizumab was associated with clinically meaningful improvements in HS signs and symptoms compared with placebo. The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx ...